To participate in this activity, please start here:
Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial results on clinical practice. They also discuss new evidence related to the burden of disease experienced by patients and caregivers and intriguing evidence pointing to the heterogeneity of atopic dermatitis.
This program is also available as a podcast. Download from Spotify or Google Podcasts
Course Credit:
1.75 AMA PRA Category 1 CreditsTM
Dates:
Opens: 2020-08-31
Closes: 2021-10-19
Target Audience:
This activity is intended for dermatologists, pediatric dermatologists, allergists, and other clinicians who manage patients with atopic dermatitis.
This activity is supported by an independent educational grant from Pfizer Inc.
-
Steven R. Feldman, MD, PhD
Professor of Dermatology, Pathology and Public Health Sciences
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, North Carolina -
Alan B. Fleischer, Jr, MD
Professor and Residency Program Director
Department of Dermatology
University of Cincinnati College of Medicine
Cincinnati, Ohio
Downloads
- Clinical Insight (124.05 KB)
- Module 2: Lebwohl Poster (350.59 KB)
- Module 3: Schlessinger Poster (389.89 KB)
- Module 4: Blauvelt Poster (698.93 KB)
- Module 5: Silverberg Poster (361.11 KB)
- Module 6: Simpson Poster (346.66 KB)
- Module 7: Owens Poster (562.47 KB)
- Module 8: Yosipovitch Poster (365.73 KB)
- Module 9: Eichenfield Poster (323.09 KB)
- Print Activity (3.70 MB)
- Slides (2.80 MB)
Learning Objectives
- Summarize the latest research developments in the pharmacologic treatment of atopic dermatitis with new and emerging agents
- Describe how new data and recommendations can impact clinical practices to improve care
- Incorporate evidence-based research into clinical practice
Faculty Disclosures
Steven R. Feldman, MD, PhD
Research support
- Abbvie
- Amgen
- Celgene
- Galderma Laboratories
- L.P.
- Janssen
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Regeneron
- Sanofi
- Taro
· Consultant
- Abbvie
- Alvotech
- Advance Medical
- Caremark
- Amgen
- Celgene
- Galderma Laboratories
- L.P.
- Gerson Lehrman Group
- Guidepoint Global
- Janssen
- Kikaku
- Leo
- Pharma Inc.
- Lilly
- Merck & Co., Inc.
- Mylan
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Regeneron
- Sanofi
- Sienna
- Sun Pharma
- Suncare Research
- Ortho Dermatology
- Xenoport
· Speakers bureau
- Abbvie
- Amgen
- Celgene
- Janssen
- Leo Pharma Inc.
- Lilly
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Regeneron
- Sanofi
- Sun Pharma
- Taro
- Ortho Dermatology
· Royalties
- Informa
- UpToDate
- Xlibris
· Stockholder
- Causa Technologies
- Medical Quality Enhancement Corporation
Alan B. Fleischer, Jr, MD
Research support
- Galderma
- Trevi
· Consultant
- Boehringer Ingelheim
- Incyte
- Qurient
- Syneos
Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Additional Content Planners
Eugene Cullen, MD (Peer Reviewer)No significant relationship to disclose
Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.